A comprehensive review published in Discover Pharmaceutical Sciences examines the integration of bioactive natural compounds with nanotechnology-based delivery systems to address the complex immunological drivers of psoriasis. The study, authored by Bhargavi Suddikattu and colleagues, analyzes how polyphenols and other herbal agents modulate key inflammatory pathways while identifying the specific translational barriers that currently limit their clinical adoption. Psoriasis is characterized by chronic immune dysregulation, leading to keratinocyte hyperproliferation and the formation of scaly plaques that affect approximately 125 million individuals globally. The review highlights that while modern synthetic therapies target specific cytokines, natural compounds offer a multi-targeted approach that may reduce the long-term immune suppression risks associated with biologic agents.
The pathogenesis of psoriasis involves a vicious cycle of inflammation driven by cytokines such as interleukin-17 (IL-17), interleukin-23 (IL-23), and tumor necrosis factor-alpha (TNF-α). These inflammatory mediators activate intracellular signaling pathways, including NF-κB and JAK/STAT, which stimulate the rapid proliferation of skin cells. The review notes that the disease is not merely a cutaneous condition but a systemic disorder linked to comorbidities such as cardiovascular disease, metabolic syndrome, and psoriatic arthritis. Understanding these molecular mechanisms is critical for developing therapies that can effectively interrupt the inflammatory cascade at multiple points rather than targeting a single receptor.
Several polyphenols have demonstrated consistent anti-psoriatic activity in preclinical models by modulating these convergent signaling axes. Curcumin, the principal polyphenol from Curcuma longa, inhibits IκB kinase, thereby preventing NF-κB activation and the subsequent transcription of pro-inflammatory cytokines. In murine imiquimod models, curcumin has been shown to reduce epidermal hyperplasia and attenuate IL-17 and IL-23 signaling. Similarly, baicalin, a flavone glycoside, modulates JAK/STAT signaling and reduces Th17-driven inflammation, offering a potentially safer alternative to synthetic JAK inhibitors despite challenges regarding solubility and extraction standardization.
Other bioactive compounds, including taxifolin, resveratrol, and epigallocatechin gallate (EGCG), exhibit potent antioxidant and anti-inflammatory properties. Taxifolin modulates Notch1 and JAK2/STAT3 signaling, significantly reducing epidermal thickness and oxidative stress biomarkers in mouse models. Resveratrol downregulates NF-κB and STAT3 pathways, suppressing Th17 differentiation and keratinocyte proliferation. EGCG inhibits STAT3 phosphorylation, which attenuates downstream IL-17 and IL-22 production. These compounds act on critical immune and inflammatory pathways, providing a mechanistic basis for their development as complementary therapeutic strategies alongside conventional treatments.
Despite their pharmacological potential, the direct clinical translation of these polyphenols is hindered by poor aqueous solubility, chemical instability, and batch-to-batch variability in botanical extracts. These limitations result in low bioavailability and inconsistent therapeutic efficacy, making it difficult to compare their performance directly with synthetic agents that have well-characterized pharmacokinetics. The review emphasizes that while these natural agents offer a favorable safety profile, their lack of robust human pharmacokinetic and pharmacodynamic data remains a significant barrier to their adoption as standard systemic therapies.
Nanotechnology-based delivery systems have emerged as a critical strategy to overcome these translational challenges. By encapsulating bioactive compounds into carriers such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), researchers can improve solubility, enhance dermal penetration, and achieve sustained release. Liposomes, which are spherical vesicles composed of phospholipid bilayers, can encapsulate both water-soluble and lipid-soluble drugs. Methotrexate-loaded liposomes, for instance, have shown efficient delivery in mouse models, significantly reducing inflammatory cytokine levels and proliferation markers while enhancing skin retention.
Solid lipid nanoparticles and nanostructured lipid carriers offer additional advantages through their solid lipid matrix, which provides improved drug stability and controlled release. In one study, methotrexate-loaded SLNs demonstrated superior permeation through cell lines, indicating potential therapeutic benefit for reducing keratinocyte proliferation. NLCs, which incorporate both solid and liquid lipids, offer superior occlusion and adhesion to the skin. Betulin-loaded NLCs, for example, produced marked lesion improvement in imiquimod-induced mouse models, accompanied by reductions in systemic inflammatory cytokines such as TNF-α, IL-6, and IL-17. These findings suggest that the therapeutic benefit of such nanosystems extends beyond local skin improvement to systemic immunomodulation.
Other nanocarrier systems, including niosomes and polymer-based nanoparticles, are also being explored for their ability to enhance dermal delivery. Niosomes, composed of cholesterol and non-ionic surfactants, provide a cost-effective and chemically stable alternative to traditional liposomes. A niosomal gel loaded with clobetasol propionate achieved a permeability rate of 61.12% in ex-vivo studies, substantially higher than the 8.56% observed for commercial cream. Polymer-based nanoparticles, such as pectin-based hydrogels loaded with tacrolimus polymeric nanocapsules, have shown improved efficacy in reducing inflammation compared to the drug alone, with significant reductions in CD4+ T cells.
The review also highlights the potential of metallic nanoparticles, such as silver and gold, which exhibit intrinsic anti-psoriatic properties. Silver nanoparticles synthesized from plant extracts demonstrated improved Psoriasis Area and Severity Index (PASI) scores and retention on psoriatic skin without irritation in rat models. Gold nanoparticle-conjugated hybrids showed potent anti-inflammatory effects, including a decreased spleen-to-body weight ratio in mice.
However, the clinical adoption of these nanoformulations faces significant regulatory and manufacturing hurdles. Most polyphenol-based nanoformulations remain at the proof-of-concept or rodent-model stage, with limited evidence of scalable manufacturing processes or long-term safety data. Regulatory bodies such as the FDA and EMA have yet to fully define approval frameworks for plant-derived nanocarrier systems, creating uncertainty regarding their path to market. The lack of standardized extraction protocols and uniform quality control standards further complicates the development of consistent, reproducible therapeutic products.
Future research directions emphasize the need for standardized extraction methods, AI-driven formulation design, and biomarker-based patient stratification. Integrating personalized medicine approaches with biomarker-guided therapy could improve treatment precision and reduce adverse effects in psoriasis management. The review concludes that while polyphenols are unlikely to compete directly with modern biologics as systemic therapies, they retain significant value as adjunctive or topical interventions when formulated in advanced nanocarrier platforms. Addressing the current limitations in stability, scalability, and regulatory clarity is essential for realizing the full translational potential of these innovative therapeutic strategies.
The review situates these natural compounds within the broader landscape of current psoriasis management, noting that conventional synthetic therapies, including methotrexate, cyclosporine, and various biologic agents, have established efficacy but are often limited by long-term side effects and immune suppression risks. In contrast, herbal therapies are characterized by a multi-targeted approach that may offer fewer adverse reactions, though they historically suffered from inconsistent dosing and poor stability. The authors argue that while synthetic drugs provide potent, targeted effects, they may focus primarily on symptom relief rather than addressing underlying systemic issues, whereas bioactive compounds can modulate multiple inflammatory pathways simultaneously. This mechanistic distinction suggests that polyphenols are best positioned as adjunctive or topical interventions rather than direct replacements for modern systemic biologics, particularly when their pharmacokinetic profiles are enhanced through advanced formulation techniques.
Specific clinical data cited in the review indicate that small molecule inhibitors, such as JAK inhibitors and PDE-4 blockers, currently demonstrate superior response rates in clinical settings, with Psoriasis Area and Severity Index (PASI) improvements exceeding 50%. These findings underscore the high benchmark against which natural compounds must compete. While polyphenols like curcumin and baicalin show promising activity in preclinical models, their effect sizes are generally lower than those of highly specific monoclonal antibodies or potent small-molecule inhibitors. Consequently, the translational value of these natural products depends heavily on their ability to achieve sufficient local concentration in the skin without causing systemic toxicity.
Emerging phytotherapeutics beyond the primary polyphenols are also examined for their potential to inhibit pro-inflammatory cytokines. The review highlights that agents such as Aloe vera and Mahonia aquifolium have shown marked inhibition of IL-17 and IL-23 in preclinical models, suggesting a broader class of herbal candidates with therapeutic relevance. Additionally, the integration of personalized medicine approaches is proposed as a future direction, where biomarker-guided therapy could help stratify patients for specific treatments. This strategy aims to improve treatment precision and reduce adverse effects by tailoring interventions to individual immune profiles. The authors suggest that combining these natural agents with standard-of-care therapies could leverage the synergistic benefits of both, potentially enhancing overall disease management while mitigating the risks associated with long-term immunosuppression.
Manufacturing and regulatory challenges remain significant barriers to the widespread adoption of these nanoformulations. The review notes that many patented nanocarrier systems represent incremental innovations rather than novel therapeutic strategies, often lacking validation in human clinical trials or demonstration of scalable manufacturing processes. Regulatory bodies, including the FDA and EMA, have yet to establish standardized approval pathways for plant-derived nanocarrier systems, creating uncertainty for developers. Without rigorous in vivo testing and translational studies, the practical impact of these patented systems remains limited. The authors stress that future research must prioritize standardized extraction protocols and comparative pharmacological studies against benchmark synthetic drugs to meaningfully assess the translational value of these polyphenols in psoriasis therapy.
Subject of Research: Exploring innovative therapeutic strategies for psoriasis treatment using bioactive compounds
Article Title: Exploring innovative therapeutic strategies for psoriasis treatment using bioactive compounds
Article References: Suddikattu, B., Tiwari, V., Tiwari, A., Marisetti, A. L., Sharma, A., Chhikara, A., & Dahiya, S. (2025). Exploring innovative therapeutic strategies for psoriasis treatment using bioactive compounds. Discover Pharmaceutical Sciences, 1(1), Article 26. https://doi.org/10.1007/s44395-025-00029-x
Image Credits: AI Generated
DOI: 10.1007/s44395-025-00029-x
Keywords: Exploring, innovative, therapeutic, strategies, psoriasis, treatment, bioactive, compounds, scientific research
News Source: Ophelia Keating. (November 7, 2026). Nanoformulations Enhance Bioactive Compounds for Psoriasis Therapy. Scienmag.
